Graefe’s Disease (Thyroid Eye Disease)

Overview

Graefe’s disease, more commonly called thyroid eye disease (TED) or Graves’ ophthalmopathy, is an autoimmune inflammatory disorder that affects the tissues around the eyes. The condition is most often associated with Graves’ disease—a hyperthyroid condition—but it can also occur with other thyroid disorders (e.g., Hashimoto’s thyroiditis) or, rarely, in people with normal thyroid function.

• Who it affects: Adults ages 30‑60 are most commonly diagnosed, with a strong female predominance (≈ 6–8 women for every man).
• Prevalence: TED occurs in 25‑50 % of patients with Graves’ disease. Overall, an estimated 0.25 % of the general population will develop clinically significant disease at some point in their lives.^{[1] National Eye Institute, 2023}
• Geographic variation: Incidence is slightly higher in Caucasian populations and lower in Asian groups, possibly reflecting differences in genetic susceptibility and smoking rates.

Symptoms

Symptoms can range from mild irritation to severe vision‑threatening complications. They often develop gradually over months, but an acute “active” phase may cause rapid worsening.

Eye‑related symptoms

• Proptosis (bulging eyes): Forward displacement of the eyeball, giving a “staring” appearance.
<
• Diplopia (double vision): Misalignment of the eyes caused by swelling of the extra‑ocular muscles.
• Dryness & irritation: Incomplete eyelid closure leads to exposure keratopathy, gritty sensation, and tearing.
• Pain or pressure: Especially behind the eyes or in the forehead during the active inflammatory phase.
• Redness & swelling: Involvement of the conjunctiva (conjunctival injection) and eyelids (eyelid edema, retraction).
• Globe displacement: In severe cases the eye may be displaced downward or laterally.
• Restricted eye movement: Stiffness of the extra‑ocular muscles leads to limited gaze in certain directions.

Vision‑related symptoms

• Blurred vision: Due to corneal surface irregularities or optic nerve compression.
• Decreased peripheral visual field: Often a sign of compressive optic neuropathy.
• Photophobia: Light sensitivity from corneal exposure.

Systemic symptoms (when associated with Graves’ disease)

• Weight loss, heat intolerance, palpitations, tremor (hyperthyroidism).
• Fatigue, cold intolerance, weight gain (if hypothyroid).

Causes and Risk Factors

TED is an autoimmune process. In genetically predisposed individuals, the immune system mistakenly attacks the orbital fibroblasts and adipocytes (fat cells) behind the eye.

Key mechanisms

• Autoantibodies: Thyroid‑stimulating immunoglobulins (TSI) cross‑react with the TSH receptor on orbital fibroblasts, stimulating inflammation and tissue expansion.
• Cytokine cascade: Release of interleukins (IL‑1, IL‑6), tumor necrosis factor‑α (TNF‑α), and fibroblast growth factor leads to fibroblast proliferation, glycosaminoglycan (GAG) deposition, and edema.
• Adipogenesis: Differentiation of fibroblasts into fat cells adds volume to the orbit, contributing to proptosis.

Risk factors

• Smoking: The most important modifiable risk factor. Current smokers have a 7‑fold higher risk of severe TED and poorer response to therapy.^{[2] ATA Guidelines, 2022}
• Gender & age: Female sex and age 30‑50 increase susceptibility.
• Severity of thyroid disease: Higher TSI titers and uncontrolled hyperthyroidism correlate with more aggressive eye disease.
• Genetics: HLA‑DRB1*03 and CTLA‑4 polymorphisms have been linked to increased risk.
• Radioiodine therapy: May precipitate or worsen TED, especially in smokers.
• Stressful events: Infections, pregnancy, and major surgery can trigger disease activity.

Diagnosis

Diagnosis is clinical but supported by imaging, laboratory testing, and standardized activity scoring.

Clinical evaluation

• History: Thyroid status, smoking, onset & progression of eye symptoms.
• Physical exam: Measurement of proptosis (Hertel exophthalmometer), eyelid retraction, ductions (eye movement), and visual acuity.

Laboratory tests

• Thyroid function tests (TSH, free T4, free T3).
• Thyroid‑stimulating immunoglobulin (TSI) or TSH‑receptor antibodies (TRAb) – positive in > 85 % of active disease.
• Inflammatory markers (ESR, CRP) may be elevated during the active phase.

Imaging

• Orbital CT or MRI: Shows enlargement of extra‑ocular muscles (characteristically sparing the tendons) and increased orbital fat.
• Ultrasound: Useful for bedside assessment of muscle thickness.

Activity & severity scoring

Two widely used tools are:

• Clinical Activity Score (CAS): 7‑point scale assessing pain, redness, swelling, and function; a score ≥ 3/7 indicates active disease.
• NO SPECS classification: Grades disease from 0 (no signs) to 6 (sight‑threatening optic neuropathy).

Treatment Options

Treatment is tailored to disease activity (active vs. inactive), severity, and the patient’s thyroid status.

General measures

• Smoking cessation: Essential; improves response to all therapies.
• Thyroid control: Achieve euthyroidism with antithyroid drugs, radioactive iodine (with steroids if needed), or thyroidectomy.
• Lubrication: Preservative‑free artificial tears, ointments, and eyelid taping at night to protect the cornea.

Medical therapies for active disease

1. Systemic glucocorticoids (prednisone 0.5‑1 mg/kg daily, tapered over 3‑6 months) – first‑line for rapid inflammation reduction. Side‑effects limit long‑term use.
2. Second‑line immunomodulators:
   • Mycophenolate mofetil – oral, can reduce steroid dose.
   • Azathioprine – alternative for steroid‑intolerant patients.
3. Targeted biologics (FDA‑approved 2020):
   • Teprotumumab – IGF‑1R (insulin‑like growth factor‑1 receptor) monoclonal antibody. Shown to reduce proptosis by an average of 3 mm and improve diplopia in > 70 % of patients.^{[3] NEJM, 2020}
   • Rituximab – anti‑CD20; mixed evidence, considered in refractory cases.
4. Orbital radiotherapy: Low‑dose (20 Gy) external beam radiation can moderate inflammation, especially when combined with steroids.

Surgical interventions (generally reserved for inactive, “quiescent” disease)

1. Eyelid surgery: Reconstructs retracted lids, improves lagophthalmos.
2. Orbital decompression: Removes bone/fat to relieve optic nerve compression and reduce proptosis; indicated for severe proptosis or optic neuropathy.
3. Strabismus surgery: Aligns the eyes after muscle fibrosis resolves.
4. Limbal or corneal procedures: Tarsorrhaphy or amniotic membrane grafts for persistent exposure keratopathy.

Adjunctive lifestyle measures

• Head elevation during sleep to reduce periorbital edema.
• Avoidance of dusty or smoky environments.
• Regular ophthalmology follow‑up every 3‑6 months during active disease.

Living with Graefe’s Disease (Thyroid Eye Disease)

While TED can be unsettling, many people manage the condition successfully with a combination of medical care and self‑care strategies.

Daily eye care

• Apply preservative‑free artificial tears at least 4–6 times daily, more often in dry or windy conditions.
• Use a warm compress for 5‑10 minutes twice daily to soothe inflamed eyelids.
• Consider a humidifier in dry indoor environments.
• Gentle eyelid massage (under ophthalmologist guidance) may improve lacrimal drainage.

Protecting the cornea

• Sleep with a soft eye mask or tape eyelids gently closed.
• If severe exposure persists, ask your eye doctor about nighttime ointment or a moisture‑gated contact lens.

Managing diplopia

• Prismatic glasses can temporarily correct double vision.
• Eye‑exercise therapy (under specialist supervision) may improve muscle coordination.

Work and lifestyle adjustments

• Notify employers about possible visual fluctuations; request frequent breaks for screen work.
• Limit alcohol and caffeine if they exacerbate thyroid instability.
• Maintain a balanced diet rich in antioxidants (vitamins C, E) to support overall eye health.

Emotional well‑being

The facial changes associated with proptosis can affect self‑image. Counseling, support groups, or referral to a mental‑health professional can be valuable.

Prevention

Because genetics cannot be changed, prevention focuses on modifiable risk factors.

• Quit smoking: Seek nicotine‑replacement therapy, counseling, or smoking‑cessation programs.
• Optimal thyroid management: Keep thyroid hormone levels within target range; work closely with an endocrinologist.
• Avoid unnecessary radioactive iodine: Discuss alternative treatments for hyperthyroidism if you have or are at risk for eye disease.
• Regular eye exams: Early detection of subtle changes can allow prompt treatment before vision is threatened.

Complications

If untreated or inadequately managed, TED can lead to serious sequelae:

• Corneal ulceration or melt: Due to chronic exposure and dryness.
• Compressional optic neuropathy: Vision loss that may be irreversible without urgent decompression.
• Permanent diplopia: Resulting from fibrosis of extra‑ocular muscles.
• Severe proptosis: Cosmetic deformity, social distress, and increased risk of trauma.
• Secondary glaucoma: Elevated intraocular pressure from orbital congestion.
• Psychological impact: Anxiety, depression, and reduced quality of life.

When to Seek Emergency Care

References

1. National Eye Institute. “Thyroid Eye Disease.” 2023. nei.nih.gov.
2. American Thyroid Association. “Guidelines for Treatment of Thyroid Eye Disease.” 2022. thyroid.org.
3. Douglas, R. et al. “Teprotumumab for Thyroid‑Associated Ophthalmopathy.” New England Journal of Medicine, 2020;382:341‑352. DOI:10.1056/NEJMoa1911085.
4. Mayo Clinic. “Graves' disease and eye problems.” Updated 2024. mayoclinic.org.
5. Cleveland Clinic. “Thyroid Eye Disease (Graves Ophthalmopathy).” 2023. clevelandclinic.org.